Skip to main content
BRAFV600E mCRC: No survival benefit of FOLFOXIRI+anti-VEGF over doublet+anti-VEGF
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
BRAFV600E mCRC: No survival benefit of FOLFOXIRI+anti-VEGF over doublet+anti-VEGF
User login
Username
Password
Reset your password
Concept
Lead
score
Colorectal Cancer
1
1
Vascular Endothelial Growth Factor
0
0.75
Tumor Genetics
0
0.85
Cancer
0
0.42
Chemotherapy
0
0.75
Specialty
Lead
score
Hematology-Oncology
1
1
Gastroenterology
0
0.91
Edit Tags